CM
ACRS icon

Caption Management’s Aclaris Therapeutics ACRS Stock Holding History

Caption Management’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-17,960
Closed -$44.5K – 1450
2024
Q4 		$44.5K Buy
+17,960
New +$44.7K ﹤0.01% 1373
2024
Q1 		– Sell
-100
Closed -$105 – 1140
2023
Q4 		$105 Sell
100
-189,900
-100% -$579K ﹤0.01% 1292
2023
Q3 		$1.3M Buy
190,000
+155,615
+453% +$1.33M 0.02% 701
2023
Q2 		$357K Sell
34,385
-186,719
-84% -$1.69M 0.01% 870
2023
Q1 		$1.79M Buy
+221,104
New +$2.81M 0.03% 472

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Caption Management's ACRS Position: Q1 2025 in Review

Caption Management sold out of Aclaris Therapeutics (ACRS) in Q1 2025, closing a stake of 17,960 shares — an estimated $44.5K sold.

Caption Management first reported a position in ACRS in Q1 2023 and held it in 5 quarters. The position peaked at $1.79M in Q1 2023. 109 funds tracked by Wall St. Rank hold ACRS as of Q1 2025.

  • Caption Management reported no remaining Aclaris Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Caption Management sold 17,960 Aclaris Therapeutics shares in Q1 2025, an estimated $44.5K.
  • Caption Management first reported a position in Aclaris Therapeutics in Q1 2023 and held it in 5 quarters.
  • Caption Management's Aclaris Therapeutics position peaked at $1.79M in Q1 2023.
  • 109 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.